Χώρα: Ηνωμένες Πολιτείες
Γλώσσα: Αγγλικά
Πηγή: NLM (National Library of Medicine)
DOXORUBICIN HYDROCHLORIDE (UNII: 82F2G7BL4E) (DOXORUBICIN - UNII:80168379AG)
Pfizer Laboratories Div Pfizer Inc
DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE 2 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. Doxorubicin Hydrochloride Injection is indicated for the treatment of - acute lymphoblastic leukemia - acute myeloblastic leukemia - Hodgkin lymphoma - non-Hodgkin lymphoma (NHL) - metastatic breast cancer - metastatic Wilms' tumor - metastatic neuroblastoma - metastatic soft tissue sarcoma - metastatic bone sarcoma - metastatic ovarian carcinoma - metastatic transitional cell bladder carcinoma - metastatic thyroid carcinoma - metastatic gastric carcinoma - metastatic bronchogenic carcinoma Doxorubicin Hydrochloride Injection is contraindicated in patients with: - Severe myocardial insufficiency [see Warnings and Precautions (5.1)] - Recent (occurring within the past 4–6 weeks) myocardial infarction [see Warnings and Precautions (5.1)] - Severe persistent drug-induced myelosuppression [see Warnings and Pre
Doxorubicin Hydrochloride Injection Doxorubicin Hydrochloride Injection is a sterile, isotonic solution, available in polypropylene (CYTOSAFE)® vials in single vial packs as: Single-dose Vials Retain in carton until time of use. Discard unused portion. Multiple-dose Vials Retain in carton until contents are used. Storage Store all vials at 2° to 8°C (36° to 46°F). Protect from light. Storage of Doxorubicin Hydrochloride Injection under refrigerated conditions can result in the formation of a gelled product. Place gelled product at room temperature [15° to 30°C (59° to 86°F)] for 2 to 4 hours to return the product to a slightly viscous, mobile solution. Handling and Disposal Doxorubicin Hydrochloride Injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.1
New Drug Application
DOXORUBICIN HYDROCHLORIDE- DOXORUBICIN HYDROCHLORIDE INJECTION, SOLUTION PFIZER LABORATORIES DIV PFIZER INC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE DOXORUBICIN HYDROCHLORIDE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DOXORUBICIN HYDROCHLORIDE. DOXORUBICIN HYDROCHLORIDE INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1974 WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, AND SEVERE MYELOSUPPRESSION _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ CARDIOMYOPATHY: MYOCARDIAL DAMAGE CAN OCCUR WITH DOXORUBICIN HYDROCHLORIDE WITH INCIDENCES FROM 1% – 20% FOR CUMULATIVE DOSES FROM 300 MG/M TO 500 MG/M WHEN DOXORUBICIN HYDROCHLORIDE IS ADMINISTERED EVERY 3 WEEKS. THE RISK OF CARDIOMYOPATHY IS FURTHER INCREASED WITH CONCOMITANT CARDIOTOXIC THERAPY. ASSESS LEFT VENTRICULAR EJECTION FRACTION (LVEF) BEFORE AND REGULARLY DURING AND AFTER TREATMENT WITH DOXORUBICIN HYDROCHLORIDE. (5.1) SECONDARY MALIGNANCIES: SECONDARY ACUTE MYELOGENOUS LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS) OCCUR AT A HIGHER INCIDENCE IN PATIENTS TREATED WITH ANTHRACYCLINES, INCLUDING DOXORUBICIN HYDROCHLORIDE. (5.2) EXTRAVASATION AND TISSUE NECROSIS: EXTRAVASATION OF DOXORUBICIN HYDROCHLORIDE CAN RESULT IN SEVERE LOCAL TISSUE INJURY AND NECROSIS REQUIRING WIDE EXCISION AND SKIN GRAFTING. IMMEDIATELY TERMINATE THE DRUG, AND APPLY ICE TO THE AFFECTED AREA. (5.3) SEVERE MYELOSUPPRESSION RESULTING IN SERIOUS INFECTION, SEPTIC SHOCK, REQUIREMENT FOR TRANSFUSIONS, HOSPITALIZATION, AND DEATH MAY OCCUR. (5.4) RECENT MAJOR CHANGES Warnings and Precautions, Embryo-Fetal Toxicity (5.8) 12/2019 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukem Διαβάστε το πλήρες έγγραφο